![1]()
News
Tools for preventing heart failure
February 13, 2020
SNOWMASS, COLO. – “There will be more than 1 million new cases of heart failure this year, and the vast majority of them could have been prevented.” – Gregg C. Fonarow, MD
![1]()
News
Medicare study evaluates impact of U.S. Hospital Readmissions Reduction Program
February 10, 2020
The proportion of care encounters studied that were preventable remains poorly understood.
![1]()
News
Cardiac arrest: Targeted temperature management a game changer
February 5, 2020
SNOWMASS, COLO. – “There are essentially no patients for whom temperature control somewhere in the range between 32 degrees C and 36 degrees C is contraindicated.”
![1]()
News
What 2019’s top five CAD trials tell us
January 29, 2020
SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.
![1]()
News
Cardiac biomarkers refine antihypertensive drug initiation decisions
January 22, 2020
PHILADELPHIA – Analysis showcases a better way to select patients for intensive BP lowering.
![1]()
News
SPRINT-type BP control provides up to 3 years of additional life
January 14, 2020
PHILADELPHIA – Survival advantage of intensive over standard blood pressure lowering is age dependent.
![1]()
News
Treatment of heart failure with preserved ejection fraction is a work in progress
January 13, 2020
Although the disorder has a lower mortality than heart failure with reduced ejection fraction, it places a significant burden on health care systems.
![1]()
News
PACT-HF: Transitional care derives no overall benefit
January 9, 2020
PHILADELPHIA – A trial of a postdischarge transitional care model found no improvement in outcomes overall, but showed that women responded more favorably than men.
![1]()
News
New hypertension performance measures boost 130/80 mm Hg target
January 6, 2020
PHILADELPHIA – Hypertension performance and quality measures from the AHA and ACC provide a guide for implementing the 2017 hypertension guideline.
![1]()
News
Farxiga granted Priority Review for treatment of adults with HFrEF
January 6, 2020
The Food and Drug Administration is reviewing dapagliflozin for reducing the risk of cardiovascular death or worsening of heart failure in adults with heart failure with reduced ejection fraction based on DAPA-HF.
